INFINITUSBIO · PUBLIC READ

Read No. EX-01

Info	Nasdaq · Small cap
Readout	Oncology · Phase 2 readout, Aug 2026
Molecule	[redacted]
Sealed	Jun 2, 2026
Fingerprint	`sha256 · 123abfd55c…01d3af`

1 The call

[redacted]

Confidence: [redacted] · Expected effect size versus control: [redacted]

2 Where it works

Indications ranked by predicted response in digitally cloned patient cells.

Rank	Indication	Predicted response	Versus standard of care
1	[redacted]	[redacted]	[redacted]
2	[redacted]	[redacted]	[redacted]
3	[redacted]	[redacted]	[redacted]

Rank	Indication	Predicted response	Versus standard of care
4	[redacted]	[redacted]	[redacted]


3 In whom

The patient cell states that respond, and those that do not, with the markers that tell them apart.

- Responders: [redacted]
- Non-responders: [redacted]
- Selection markers: [redacted]

4 Why

The mechanism: how the drug's effect on its targets travels through the cell to the outcome.



[redacted]

5 Versus the standard of care

Head to head with the standard of care and other drugs, in the same cloned cells.

- Standard of care: [redacted]
- This molecule: [redacted]
- Difference: [redacted]

6 If it falls short alone

The combinations with the standard of care or other drugs that change the answer.

- Best combination: [redacted]
- Predicted gain: [redacted]
- Patients most likely to benefit: [redacted]

7 Inputs and method

Public data used: [redacted]. Number of cell states simulated: [redacted]. No training data. The same inputs always give the same read.

8 Limits of this read

An efficacy call, not clinical evidence. It does not cover safety, dosing or

regulatory outcome. [redacted]

Check the seal: hash this report’s statement with SHA-256 and compare it with the fingerprint on the Ledger.

Sample for illustration. Efficacy calls are not clinical evidence and are not investment advice.